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Abstract

The aim of our paper is to highlight the main therapeutic principles and the management
options in the case of a diabetic patient who has had a sudden hearing loss. Mainly, the aim is to
underline the sudden hearing loss treatment adjustment of the diabetic patient compared to the
non-diabetic patient.
By understanding the mechanism of sudden hearing loss in a diabetic patient, namely the
impact of glycemic variations and their implication on the microvascular structures of the inner
ear, we try to underline the treatment principles and management options of the previously
mentioned combined pathologies.
Thus, it is necessary to adapt the classes of drugs used in the case of sudden sensorineural
hearing loss of the diabetic patient in comparison with the non-diabetic patient, in order not to
aggravate or complicate the patient’s functional status. Therefore, the treatment will need to be
adapted both by classes of medication and by the type of administration used.
Adequate control of the progression, treatment and complications of diabetes mellitus ensures
optimal treatment management in case of a sudden hearing loss and therefore interferes with the
favorable functional hearing outcomes.
The role of this paper is not only to state the therapeutic principles in the case of sudden
hearing loss in a diabetic patient, but also to analyze the impact on the management of potential
local and systemic risk factors.

Keywords



Highlights

 The diabetic patient represents one of the challenges of current medicine, by the
complexity of multiple organ disorders associated with this pathology, its evolution and
treatment particularities.
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 Vasculopathies and neuropathies are frequent complications in the course of the illness
and sudden hearing loss comes with significant damage to the quality of life.
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Introduction
Nowadays, one of the comorbidities that, if not
adequately treated, have an increased potential for
developing complex and extensive complications is
known to be diabetes mellitus (DM). This condition is one
of the fastest developing chronic pathologies of the
moment.
Diabetes is a disease that involves a series of
metabolic afflictions determined by modified insulin
secretion and following the altered and adjusted actions of
the previously mentioned hormone that defines a higher
level of blood sugar. This metabolic damage may
determine misuse of proteins, fats and carbohydrates that
make the body readapt and create compensatory
mechanisms to work by the new dictated parameters.
Hyperglycemia, emerged as compensation for the new
metabolic changes, determines the poor functioning of
various systems and organs.
Because the diabetic patient has either a severely
deficient insulin production or the body is not capable of
using the insulin produced by the pancreas, there are two
main types of diabetes mellitus described in the literature.
Type I Diabetes Mellitus is defined as the autoimmune
destruction of the beta-cells within the pancreas, while the
patients suffering from this condition are insulindependent and need to pay attention to their glycemic
values, to accurately control blood glucose levels during
the day. This type of diabetes is found in children and
adolescents.
Type II Diabetes Mellitus is defined by an inadequate
response of fat and muscle cells of the body to insulin and
a compensatory production of insulin by the liver to try
and dispute that improper response. This type of diabetes
is typical in adults, frequently associated with obesity and
may or may not be insulin-dependent, depending on the
moment when diabetes is discovered.
Thus, as diabetes progresses, it can lead to different
complications such as nephropathy, neuropathy,
oculopathy, microangiopathy and even heart conditions
(1).
A possible, but not so much discussed complication of
this condition is hearing impairment and, usually, in the
case of a diabetic patient, the hearing loss is bilateral,
sensorineural, symmetrical and with a tendency of mainly
affecting the low and mid frequencies.
Specialty literature studies show that when discussing
diabetic patients, they are more susceptible to developing
sudden sensorineural hearing loss than non-diabetic
patients, especially as a result of microvascular
complications (2).
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This paper mainly aims to underline the sudden
hearing loss treatment adjustments of the diabetic patient
compared to the non-diabetic one.

Discussions
The sudden idiopathic hearing loss represents a form
of acute hearing loss audiometrically expressed as a
sensorineural hearing loss higher than 30dB, on three
consecutive
frequencies,
with
an
onset
of
symptomatology of maximum 72 hours before the
presentation of the patient to the ENT physician’s office.
In most cases, it is unilateral, the prognosis of hearing
recovery being often favorable.
The pathogenic mechanism is not readily identifiable,
since there are very few cases in which it is possible to
tell with precision what hearing loss was caused by (3).
Specialty literature mentions the involvement of
infectious factors (viral or bacterial), vascular
(hemorrhagic or ischemic), autoimmune (Cogan's disease,
autoimmune
thyroiditis,
sarcoidosis,
Wegener's
granulomatosis), tumors (acoustic neurilemmoma which
often causes slow progressive hearing loss without
excluding a possible clinical onset in the form of sudden
hearing loss), traumatic, chemical or toxic causes
(ototoxic medication), etc. (4). Suddenly installed hearing
loss is a medical emergency, although some literature
studies have shown that, in some cases, hearing may
improve even if no treatment is administered.
Nevertheless, it is worth mentioning that the presence
of other conditions such as hypertension, diabetes
mellitus, dyslipidemias, and even the age of the patient,
can lead to a bad response compared to patients who do
not suffer from the previously mentioned conditions (5).
These comorbidities directly or indirectly influence the
appearance, evolution, responsiveness to treatment and
prognosis of the sudden hearing loss (6).
However, literature has not shown yet if the associated
comorbidities and age influence, together or separately,
the prognosis of patients who have sudden sensorineural
hearing loss.
An essential element to be mentioned is that diabetes,
as well as other comorbidities, influence the therapeutic
strategy that the patient needs to undertake, due to the
certain possible complications that might occur and may
or may not contraindicate specific therapies (7-9).
Researchers investigated the prevalence of diabetes in
patients with sudden idiopathic sensorineural hearing loss
compared to a diabetic patient with normal hearing and
revealed that it was almost double. It seems that through
cerebral microangiopathy and due to diabetic changes in

Hearing loss in a diabetic patient
blood viscosity, sudden idiopathic sensorineural hearing
loss is mediated in a diabetic patient, although the proper
mechanism which determines hearing loss has not been
discovered yet (10).
Several studies conducted on humans have shown the
thickening of the capillary walls of the stria vascularis, the
basilar membrane and the endolymphatic sac,
atherosclerotic narrowing of the internal auditory artery,
atrophy of the stria vascularis, loss of outer hair cells
(OHCs) mainly in the lower basal cochlear turn, spiral
ganglion neural atrophy, and VIII cranial nerve
demyelination (11, 12).
A rigorous anamnesis, as well as a detailed history of
the disease, can provide important elements that will lead
to a possible cause or triggering factor of the suddenly
installed hearing loss.
Practice guidelines strongly recommend the correct
differentiation between sensorineural hearing loss
(SNHL) and conductive hearing loss in patients who
undergo an episode of sudden hearing loss (Figure 1).

Figure 1. Left - Sensorineural hearing
loss; Right - Conductive Hearing loss
Several elements help establish a definite diagnosis in
case of suddenly installed hearing loss:
o Pure tone audiometry, vocal audiometry and
acoustic immittance, which are routine audiometric tests;

o Otoscopy to appreciate the local appearance of the
external auditory meatus and the tympanic membrane and
thus eliminate possible local causes that could determine
sudden hearing loss;
o Instrumental measuring of hearing acuity using a
512Hz tuning fork that helps differentiate between
sensorineural hearing loss and conductive hearing loss in
an emergency room (bilateral positive Rinne, Weber
lateralized in the healthy ear) (Figure 2.);

Figure 2.
512Hz tuning Fork

o Brainstem auditory evoked potential that helps
identify the possible lesional headquarters by studying the
distinctions between ears in terms of the differences
between the I-III and I-V intervals;
o Magnetic Resonance Imaging using contrast medium
is considered to be “the gold standard” method in
identifying an acoustic neuroma, a labyrinthine
hemorrhage, an inflammatory process or an
endolymphatic hydrops;
o Vestibular evaluation to complement the patient's
clinical examination if there is vestibular symptomatology
(vertigo, imbalance) in addition to hearing loss. In
patients experiencing a vertiginous crisis, this
examination should be performed at the head of the bed
and involves the evaluation of nystagmus, oculomotricity,
and the development of evidence to help differentiate
between central and peripheral vertigo (13).
The treatment administered in case of sudden hearing
loss is non-specific and attempts to cover the possible
pathogenic mechanisms involved. There are some
treatment principles and options which are worth
mentioning, but in the case of a diabetic patient, the
essential element that always has to be taken into account
when choosing and controlling the treatment and
prognosis of a sudden idiopathic hearing loss is the blood
glucose level. The treatment strategy is also influenced by
the age of the patient, gender, body mass index, presence
of tinnitus, dizziness, ear fullness sensation and presence
of cerebral microangiopathy besides associated diseases
(6, 10).
Thus, here are the main therapeutic options used in the
treatment of sudden idiopathic sensorineural hearing loss:
Anti-inflammatory agents such as corticosteroids,
whose role is to reduce perineural auditory and cochlear
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inflammation, influencing any anti-inflammatory or
immunosuppressive reaction and vascular permeability
(14). This is the most common treatment used in sudden
idiopathic sensorineural hearing loss, but it should never
be used in high dosage therapy in case of diabetic
patients, since it determines the increase of blood glucose
levels and may lead to poor prognosis. A more extended
treatment regarding the period of drug administration with
lower dosage is preferable in diabetic patients compared
to non-diabetic patients, in whose case higher dosage
therapy is used. Literature highlights the use of intratympanic cortisone, but with low good outcomes
compared to oral cortisone therapy (15).
The use of Vasodilators such as Lipo-Prostaglandin
E1 is justified by their ability to improve the blood flow
to the cochlea and thus prevent local hypoxia. The
duration of diabetes and the pre-existence of
microvascular diabetic complications may compromise
the use of these agents (16).
Rheological agents are also used, since they improve
oxygen flow by modifying blood viscosity through the
use of low-molecular-weight dextrans, pentoxifylline or
anticoagulants (heparin, warfarin). The use of these
medications may cause hypoglycemia, so special care
should be taken not to decompensate the patient's diabetes
and to properly adjust the treatment of the associated
conditions before initiating the treatment for the sudden
hearing loss (9).
Antiviral agents are used only if a viral cause is
suspected. Literature describes a limited use of acyclovir
and amantadine in the treatment of sudden idiopathic
hearing loss. Taking into account that the diabetic patient
has a compromised and irregular reactive immune system,
the probability of contacting a viral infection increases,
thus the idea of associating antiviral agents in the
treatment of sudden idiopathic hearing loss in a diabetic
patient is strongly recommended (9, 10).
Diuretics or diuretic-like medication are used when
there is a suspicion of endolymphatic hydrops, since these
drugs can help reduce the fluid pressure load that can
occur in the inner ear. They are helpful while trying to
prevent an attack, but lack effectiveness in case of an
already triggered attack. Diuretics or diuretic-like
medication may decrease the effectiveness of the oral
antidiabetic treatment (9).
Supplementation with vitamin D can bring a modest
benefit to the diabetic patient with hearing loss. The role
of vitamin D is well known in chronic pathology and is
now considered to be a vitamin-hormone with multiple
beneficial actions. In most cases, the benefit is maximum
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if associated with magnesium. Vitamin D deficiency can
lead to a degree of osteoporosis of the temporal bone,
which will affect the transmission of sounds. Some
studies even suggest supplementation with vitamin D
intrapartum to prevent congenital deafness (17, 18).
Hyperbaric oxygen therapy, if used since the early
stages, can significantly improve hearing loss. Salvage
therapy with hyperbaric oxygen results are compared in
the literature with the results obtained by using
corticosteroids, thus being considered an effective
treatment option (19-21).
Carbogen inhalation. This gas is composed of 95%
Oxygen and 5% Carbon dioxide. It is believed that the
administration of this combination of gases, will result in
the vasodilation of the inner ear and increased blood flow
and oxygen to the damaged hair cells that may encourage
hearing loss recovery if a vascular disorder was the cause
of it. The benefits of this therapy have been debated over
the years, but ENT specialists have not reached a final
decision yet. According to Kallinen et al., this inhalation
therapy was proven to be more useful in patients with a
low response on flat and high-pitched tones (22, 23). In a
clinical analysis in 2004, Ni y. et al. concluded that drug
therapy combined with Carbogen administration has
better results in treating sudden hearing loss (24). Some
authors suggest a five day-course of inhaler
administration for an hour a day and others elect a shorter
course of 3 days, but with a more intensive frequency: 10
minutes every hour while the patient is awake. As Ni y.
and others concluded that Carbogen use is an excellent
adjuvant in the systemic drug treatment.
Studies have shown that treatments for sudden
idiopathic hearing loss based on the use of corticosteroids,
i.e. lipo-Prostaglandin E1 and carbogen gas inhalation, are
more effective than other treatment strategies studied and
have great results even in patients with diabetes mellitus
(25).
Regarding the prognosis of suddenly installed hearing
loss, its spontaneous recovery rate is generally good
(approximately 47-63%, according to specialty studies),
but depending on associated comorbidities, such as
diabetes and its complications, as well as the onset of the
treatment administered depending on the duration of
diabetes, glycemic control and the onset of the sudden
idiopathic hearing loss, it is associated with a lower
recovery rate.
It has been shown that the more severe the hearing
loss, associated with a lack of proper diabetes control and/
or diabetic complications, the more unfavorable the
prognosis.

Hearing loss in a diabetic patient
Patients who do not fully recover hearing may be
advised on the possibilities of hearing impairment
depending on age, degree of hearing loss and associated
comorbidities.
Although in most cases, hearing loss associated with
diabetes is bilateral, sensorineural, symmetrical and with
a tendency of mainly affecting the low and mid
frequencies, there are cases in which a sudden idiopathic
sensorineural hearing loss can occur.
A sudden idiopathic sensorineural hearing loss in a
diabetic patient can have a bad onset with deep hearing
loss compared to the case of a non-diabetic person,
depending on blood glucose levels, pre-existent
management and complications of diabetes and can also
associate poor prognosis and recovery as well as lack of
treatment compliance.
Periodic and constant blood glucose level control
helps adapt the treatment for hearing loss properly.
The most effective medications for the treatment of
sudden idiopathic sensorineural hearing loss in a diabetic
patient are equally considered to be the corticosteroids,
i.e. lipo-prostaglandin E1 and Carbogen gas inhalation.
The availability of certain treatment options as well as
the time passed between the patient’s presentation to the
physician and the onset of hearing loss or the initiation of
the treatment are important elements that dictate the
prognosis of hearing recovery as well as the efficiency of
the treatments of choice. Although, as previously
described, there is a wide range of therapeutic options that
can be used in the case of sudden idiopathic hearing loss,
most of them ranked as non-specific, their availability and
degree of applicability to each individual that must be
treated are some of the major challenges of an ENT
physician.
Another important factor that dictates the prognosis
and the good course of treatment is the patient’s
reluctance towards some non-infusible or drug-staging
treatments and, in the absence of appropriate medical
knowledge or a good understanding of the effectiveness
of these therapeutic options, they are categorized as
unconventional by the patient and do not make him
choose this specific treatment despite its availability,
namely Carbogen gas inhalation or hyperbaric oxygen
therapy.
Diabetes belongs to a pathological field in which
constant advances are made regarding the available
therapies. As in other specialties, such as neurology,
cardiology or oncology, on-going studies and research
give us more and more options regarding the treatment of
choice (26, 27). Especially in cases where diabetes is

associated with other comorbidities, the therapy options
are limited by the patient’s general condition and
tolerance to aggressive treatments.
Unfortunately, there is no international consensus
regarding the treatment of sudden hearing loss. There are
some American authors who recommend cortisone
therapy for one month from the onset of hearing loss and
there are some French authors who recommend cortisone
therapy for 10 days from the onset of hearing loss.
Moreover, there are differences of opinion regarding the
proper moment for therapy initiation, given the moment
of hearing loss occurrence. Some authors maintain the
hypothesis of its important initiation in the first 24 to 72
hours, while others allow initiation even up to 5-7 days
after the onset of sudden hearing loss. We are talking
about the existence of a high risk of malpractice and a
questionable therapeutic attitude that depends on the
clinical experience and constantly improved medical
knowledge of the ENT physician.
This lack of pre-established therapeutic protocols
compared to other pathologies, such as cancer or any
other well-known and classified disease in terms of
staging and treatment options, creates a tendency of
treatment adaptation at a national level, in relation with
geographic, cultural and socio-economic factors.

Conclusions
Diabetes mellitus, as one of the fastest developing
chronic pathologies of the moment, is defined by a group
of metabolic disorders which could determine a complex
series of complications that affect the eyes, kidneys,
nervous system and peripheral blood vessels.
Sudden idiopathic sensorineural hearing loss that
occurs in patients with diabetes mellitus has been
associated with more severe hearing loss and also with
poor prognosis that could become irrecoverable in case no
treatment is administered and it also regards the duration
of diabetes, the onset of the hearing loss, as well as the
presence or absence of diabetic comorbidities, the age of
the patient and other associated conditions.
Similarly, the post-prandial glucose level and the
proper control of blood glucose levels are more likely to
affect the evolution of the disease.
Sudden idiopathic sensorineural hearing loss occurring
in a patient with arterial hypertension, diabetes mellitus or
dyslipidemia or in elderly patients, is associated with an
increased prevalence of cerebral microangiopathy,
highlighted by magnetic resonance imaging, and it
determines a slower hearing recovery, as shown if
following the improvements in speech discrimination
tests.
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